Sugi Predict

Sugi Predict / Compounds / Teriparatide

Teriparatide

Teriparatide

SCHEMBL720581

CC(=O)O.CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTH1R

The experimentally established mechanism targets of Teriparatide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ PTH1R known ✓ Q03431 14/20 0.90
▸ GLP1R P43220 5/20 0.74
▸ CCKBR P32239 1/20 0.74
▸ ECE1 P42892 1/20 0.70
▸ MUS81 Q96NY9 1/20 0.70
▸ RXFP1 Q9HBX9 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Teriparatide SCHEMBL29354459 0.99 PTH1R (0.91) PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL28980015 0.99 PTH1R (0.91) PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL1773403 0.96 PTH1R (0.85) PTH1RGLP1RCCKBRECE1MUS81
Teriparatide SCHEMBL29357752 0.96 PTH1R (0.85) PTH1RGLP1RCCKBRECE1MUS81
SCHEMBL29357289 0.94 PTH1R (0.88) PTH1RGLP1RCCKBR
Teriparatide SCHEMBL30448707 0.93 PTH1R (0.80) PTH1RGLP1RCCKBRRXFP1
Teriparatide SCHEMBL29394193 0.93 PTH1R (0.80) PTH1RGLP1RCCKBRRXFP1
SCHEMBL30255063 0.93 PTH1R (0.80) PTH1RGLP1RCCKBRRXFP1
SCHEMBL28980125 0.93 PTH1R (0.80) PTH1RGLP1RCCKBRRXFP1
Teriparatide SCHEMBL30645329 0.93 PTH1R (0.80) PTH1RGLP1RCCKBRRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260139239-A1 VARIANTS OF TEV PROTEASE AND USES THEREOF NUMAFERM GMBH (DE) 2026-05-21 — — US disclosed
EP-4569098-A1 VARIANTS OF TEV PROTEASE AND USES THEREOF NUMAFERM GmbH (DE) 2025-06-18 — — EP disclosed
WO-2024033427-A1 VARIANTS OF TEV PROTEASE AND USES THEREOF NUMAFERM GMBH (DE) 2024-02-15 — — WO disclosed
CN-112679603-B Method for preparing teriparatide by solid-liquid phase combination 苏州特瑞药业股份有限公司 2023-09-22 — — CN disclosed
CN-114137114-A Teriparatide isotope internal standard, preparation method and application thereof 信立泰(苏州)药业有限公司 2022-03-04 — — CN disclosed
US-11248037-B2 Multivalent heteromultimer scaffold design and constructs ZYMEWORKS INC. (CA) 2022-02-15 — — US disclosed
CN-107501408-B Preparation method of teriparatide 扬子江药业集团四川海蓉药业有限公司 2021-11-02 — — CN disclosed
CN-112679603-A Method for preparing teriparatide by solid-liquid combination 苏州特瑞药业有限公司 2021-04-20 — — CN disclosed
US-10711051-B2 Multivalent heteromultimer scaffold design and constructs ZYMEWORKS INC. (CA) 2020-07-14 — — US disclosed
US-20190127443-A1 MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS ZYMEWORKS BC INC. (CA) 2019-05-02 — — US disclosed
WO-2006113914-A2 METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2006-10-26 — — WO disclosed
EP-1689228-A2 METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS Fred Hutchinson Cancer Research Center (US) 2006-08-16 — — EP disclosed
EP-1684579-A1 METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS Fred Hutchinson Cancer Research Center (US) 2006-08-02 — — EP disclosed
EP-1684580-A2 METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS Fred Hutchinson Cancer Research Center (US) 2006-08-02 — — EP disclosed
US-20050170019-A1 Methods, compositions and devices for inducing stasis in cells FRED HUTCHINSON CANCER RESEARCH CENTER 2005-08-04 — — US disclosed
US-20050147692-A1 Methods, compositions and devices for inducing stasis in tissues and organs FRED HUTCHINSON CANCER RESEARCH CENTER 2005-07-07 — — US disclosed
US-20050136125-A1 Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-06-23 — — US disclosed
WO-2005041655-A1 METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2005-05-12 — — WO disclosed
WO-2005041656-A2 METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2005-05-12 — — WO disclosed
WO-2005039291-A2 METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2005-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260139239-A1 VARIANTS OF TEV PROTEASE AND USES THEREOF CTRL, MME, MMEL1 PTH1R 3264/4885GLP1R 2925/4885CCKBR 4031/4885
US-20050147692-A1 Methods, compositions and devices for inducing stasis in tissues and organs HIF1A, HIF1AN, PYGL PTH1R 526/4885GLP1R 1204/4885CCKBR 800/4885
US-20050136125-A1 Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms HSF1, HSP90AB1, HSP90AA1 PTH1R 526/4885GLP1R 2358/4885CCKBR 554/4885
US-20050170019-A1 Methods, compositions and devices for inducing stasis in cells PLAT, TBXA2R, THPO PTH1R 997/4885GLP1R 1113/4885CCKBR 1364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.